Natixis Advisors LLC Purchases 476,073 Shares of Pfizer Inc. $PFE

Natixis Advisors LLC raised its position in Pfizer Inc. (NYSE:PFE) by 27.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,205,275 shares of the biopharmaceutical company’s stock after purchasing an additional 476,073 shares during the period. Natixis Advisors LLC’s holdings in Pfizer were worth $54,912,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Camden National Bank lifted its holdings in shares of Pfizer by 4.4% during the 4th quarter. Camden National Bank now owns 11,842 shares of the biopharmaceutical company’s stock worth $295,000 after acquiring an additional 501 shares during the last quarter. Vantus Wealth LLC bought a new stake in shares of Pfizer during the 4th quarter worth $467,000. Root Financial Partners LLC lifted its holdings in shares of Pfizer by 18.5% during the 4th quarter. Root Financial Partners LLC now owns 9,287 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 1,450 shares during the last quarter. BNP Paribas lifted its holdings in shares of Pfizer by 85.8% during the 4th quarter. BNP Paribas now owns 635,974 shares of the biopharmaceutical company’s stock worth $15,842,000 after acquiring an additional 293,744 shares during the last quarter. Finally, Collar Capital Management LLC lifted its holdings in shares of Pfizer by 3.8% during the 4th quarter. Collar Capital Management LLC now owns 40,235 shares of the biopharmaceutical company’s stock worth $1,002,000 after acquiring an additional 1,470 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PFE shares. HSBC lifted their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Guggenheim lifted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Morgan Stanley lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.82.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s oncology pipeline drew renewed optimism after ASCO 2026 data showed encouraging Phase 3 results for BRAFTOVI in metastatic colorectal cancer and TALZENNA in prostate cancer, reinforcing the company’s long-term growth story. Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story
• Positive Sentiment: Jefferies reiterated a buy rating on Pfizer, and another report highlighted Pfizer as undervalued, which may help support sentiment around the stock’s current valuation. Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
• Positive Sentiment: Pfizer also received coverage suggesting its obesity and oncology pipeline could deliver multiple catalysts in 2026, keeping investors focused on upcoming data readouts and regulatory events. Pfizer’s Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
• Neutral Sentiment: Pfizer presented at the Jefferies Global Healthcare Conference, but the transcript appears to be mainly a routine investor update rather than a major new announcement. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Pfizer also announced updates on its ODEN ulcerative colitis study and completed a bevacizumab biosimilar safety study in Japan, both of which are incremental pipeline updates rather than immediate stock-moving breakthroughs. Pfizer’s ODEN Study Update: Real-World Data on Tofacitinib in Ulcerative Colitis
• Negative Sentiment: Some articles continue to frame Pfizer as a high-yield stock facing patent-cliff concerns and competitive comparisons with peers like Bristol Myers and Merck, which may weigh on sentiment despite the company’s pipeline progress. Bristol Myers vs. Pfizer: Which High-Yield Dividend Stock Wins Now?

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.37 on Thursday. The stock has a market cap of $144.57 billion, a PE ratio of 19.36 and a beta of 0.34. The company’s fifty day moving average is $26.68 and its 200 day moving average is $26.29. Pfizer Inc. has a 52 week low of $23.08 and a 52 week high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.